Dr. Carolyn Britten on Next Steps in Immunotherapy
In Partnership With:
Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
Other types of novel therapies are
necessary
.
Immunotherapy offers a lot of promise to the field of oncology, says Britten, but it is not the only option.
Proper patient selection will be the key to best utilizing immune checkpoint blockage therapies, she says. A better understanding of which combinations work best is also needed.
